Klimek, LudgerBrehler, RandolfMösges, RalphDemoly, PascalMullol i Miret, JoaquimWang, De YunO'Hehir, RobynDidier, AlainKopp, Matthias VolkmarBos, CatherineKaragiannis, Efstratios2023-06-212023-06-212022-06-152164-554Xhttps://hdl.handle.net/2445/199544Sublingual immunotherapy (SLIT) is a well-tolerated, safe, and effective approach to treating allergic rhinitis (AR). Oralair (R) is a five-grass pollen SLIT tablet containing natural pollen allergens from five of the major grass species responsible for seasonal AR due to grass pollen allergy. Recommended use is in a pre-coseasonal regimen, starting daily treatment approximately 4 months before the start of the pollen season, with treatment then continued daily throughout the season; treatment should continue for 3-5 y. Clinical efficacy and safety of Oralair (R) in patients with grass pollen-induced AR has been demonstrated in a comprehensive clinical development program of randomized controlled trials. Effectiveness has been substantiated in subsequent observational studies with sustained efficacy following treatment cessation and a favorable level of adherence, quality of life, benefit, and satisfaction for the patients. Supportive evidence for a benefit in reducing the risk or delaying the development of allergic asthma is emerging.10 p.application/pdfengcc by-nc-nd (c) Klimek, Ludger et al, 2022http://creativecommons.org/licenses/by-nc-nd/3.0/es/RinitisGramíniesAntihistamínicsRhinitisGrassesAntihistaminesinfo:eu-repo/semantics/article2023-06-20info:eu-repo/semantics/openAccess931590035704772